AlphAIalphai — Financial news for AI agents
SEC EDGARJUL 22 min read$DRTS

Levy Raphi sold $28K of DRTS

Levy Raphi (Chief Financial Officer) sold 2,127 shares of Alpha Tau Medical Ltd. (DRTS) at $13.02 on 2026-07-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Levy Raphi
Published Jul 2, 2026, 3:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 3:51 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$DRTS
Neutral
high confidence
Mentioned
$DRTS
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$DRTSNeutralLow
01

Why it matters

The newest disclosed fact is the specific open-market sale size, price, and that it was executed under a pre-arranged 10b5-1 plan; no new company fundamentals are provided.

02

Market read

Insider selling confirmation may slightly influence sentiment, but the modest size and 10b5-1 context suggest limited trading impact.

03

What to watch

The filing does not state reasons for the sale or any concurrent buying; traders should avoid over-weighting small-value insider sales without corroborating fundamentals.

Relevance 2/10Novelty 3/10Timing: Form 4 filed 2026-07-02 for a 2026-07-01 sale

Background

This is an SEC Form 4 insider transaction for Alpha Tau Medical Ltd. (DRTS), reported by CFO Levy Raphi.

Company-level read

Ticker impact

$DRTSNeutralHigh confidence
Context

Alpha Tau Medical CFO Levy Raphi sold 2,127 shares on 2026-07-01 under a pre-arranged 10b5-1 plan, worth about $27.7K.

Expected impact

Likely minimal near-term impact; any effect is more about sentiment than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and modest dollar value, with no accompanying operational or guidance change disclosed.

Market effects

Sector

No sector read-through; this is company-specific insider liquidity with no disclosed business catalyst.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a 10b5-1 plan, it may reflect scheduled diversification rather than bearish expectations.

Key entities

  • issuer
    Alpha Tau Medical Ltd.

    Company whose insider transaction is disclosed via Form 4.

  • insider
    Levy Raphi

    Chief Financial Officer reporting the sale.

  • trading mechanism
    10b5-1 plan

    Pre-arranged plan that reduces interpretive weight of the sale.

Read at source← All news

Related articles

JUL 15
$DRTSMed

Alpha Tau Successfully Treats First Immunocompromised Patient with Recurrent Cutaneous Squamous Cell Carcinoma in its ADMIRE Study at Banner MD Anderson Cancer Center

Alpha Tau Medical Ltd. (Nasdaq: DRTS) said Banner MD Anderson Cancer Center treated the first immunocompromised patient in its ADMIRE trial of intratumoral Alpha DaRT for recurrent cutaneous squamous cell carcinoma. ADMIRE is a prospective, open-label, single-arm study enrolling up to 28 patients, with objective response rate as the primary endpoint.

manilatimes.net4 min
JUN 23
$DRTSMed

Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel

Alpha Tau Medical Ltd. (Nasdaq: DRTS, DRTSW) said it treated the first recurrent glioblastoma patient in Israel and the first outside the U.S. with its Alpha DaRT® system at Hadassah University Medical Center in Jerusalem. The company said the minimally invasive stereotactic procedure used a brain applicator and was completed without unexpected complications under the ALL protocol.

manilatimes.net3 min
JUN 4
$DRTSMedAI 9/10

Alpha Tau And Tolmar Form Strategic Collaboration In U.S. Prostate Cancer

Alpha Tau Medical (DRTS) and Tolmar International announced a U.S. collaboration to develop and commercialize Alpha DaRT for prostate cancer. Tolmar will have exclusive U.S. commercialization rights for 20 years from first sale, with an option to expand to bladder cancer after milestones. Tolmar will invest $15m in manufacturing, add $20m equity at $11.99/share, and pay up to $161.5m in milestones; Alpha Tau will supply product at 60% of onward net sales.

rttnews.com4 min